09:41 AM EDT, 08/28/2024 (MT Newswires) -- AC Immune ( ACIU ) said Wednesday that the US Food and Drug Administration has issued a Fast Track Designation for the PI-2620 Tau positron emission tomography, or PET, imaging agent that the company is developing with privately held Life Molecular Imaging to diagnose three neurodegenerative conditions, including Alzheimer's disease.

The Fast Track Designation also covers PI-2620 as a potential diagnostic for progressive supranuclear palsy and corticobasal degeneration, AC Immune ( ACIU ) said.

PI-2620 is in phase 3 clinical development for detecting Tau pathology in Alzheimer's disease and could eventually be adapted also for non-Alzheimer tauopathies such as progressive supranuclear palsy and corticobasal syndrome, the company said.

AC Immune ( ACIU ) rose nearly 2% in early trading Wednesday.

Price: 3.1200, Change: +0.06, Percent Change: +1.96